New York, June 11, 2026, 10:46 AM EDT
• Pfizer stock rose about 2.7% to around $26.28 in late Thursday trading.
• RBC Capital moved its rating on Pfizer up to Sector Perform from Underperform, sticking with the $25 target.
• Reuters said new German drug-pricing plans are adding another risk for global pharma companies.
Pfizer Inc. shares gained Thursday. PFE was last at $26.28, up 68 cents from its previous $25.60 close. The stock started the session at $25.85, hitting a low of $25.61 and a high of $26.48. Volume had cleared 15.6 million shares by late morning.
Pfizer shares outpaced the broader market. The SPDR S&P 500 ETF Trust gained 0.38% and the Health Care Select Sector SPDR ETF added 0.81%. Pfizer jumped about 2.7%.
RBC Capital lifted its rating on Pfizer to Sector Perform from Underperform and put a $25 target on the stock. RBC pointed to valuation after Pfizer’s drop from 2026 highs, saying risk and reward now look more balanced, per Investing.com.
RBC’s upgrade to Sector Perform with a $25 price target showed up as the latest Pfizer rating change on Benzinga’s analyst tracker. The tracker left Pfizer with a Hold-like overall call. Google Finance also showed 23 analysts: 8 Buy, 13 Hold, and 2 Sell, with the group averaging a $29.05 12-month target.
Pfizer shares pushed higher despite a fresh policy risk out of Europe. Reuters said Wednesday that CEO Albert Bourla told German Chancellor Friedrich Merz the company is now looking at the timing and size of planned investments in Germany because of a proposal to cut drug prices.
Pfizer CEO Albert Bourla said in a June 9 letter that the company is reassessing its external partnerships and the timing and scope of some planned investments in Germany. Pfizer did not say which investments are being reconsidered and did not comment further to Reuters.
Pfizer investors have been watching the pricing fight in Germany as it ties into the worldwide wrangling over drug prices, U.S. pricing policy, and where pharma companies put their money. Reuters reported that Eli Lilly cut a planned $2.3 billion investment in Germany by half, and Boehringer Ingelheim dropped €900 million in spending plans. Both moves were blamed on looming cuts in healthcare spending.
Wall Street’s tone was risk-on early Thursday as tech stocks bounced. Major U.S. indexes moved up with the Dow up 0.90%, S&P 500 gaining 0.81%, and Nasdaq up 1.07% by 9:56 a.m. ET, Reuters said. Investors stepped back into some of the tech names that have dropped lately.
Pfizer is still betting its stock story on whether it can hold on to its 2026 forecast and spark new growth after the drop in COVID business. In its first-quarter update, Pfizer posted revenue of $14.45 billion, up 5% from a year ago. Adjusted diluted EPS came in at $0.75. The company kept its full-year 2026 revenue target intact at $59.5 billion to $62.5 billion, with adjusted diluted EPS projected between $2.80 and $3.00.
Income is still central for some Pfizer shareholders. Google Finance put the company’s quarterly dividend at $0.43, with a yield above 6%. Pfizer’s first-quarter update said it returned $2.4 billion to shareholders as cash dividends in the first three months of 2026. It left out share repurchases from its 2026 guidance.
Pfizer’s shares are now trading more in the middle of their 52-week range than at the top. Google Finance shows the range at $23.11 to $28.74, and the market remains focused on whether pipeline updates, the dividend, and cost moves will be enough to beat pressure in Europe and doubts about Pfizer’s post-COVID reset.
